Vol.64

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.63

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.62

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.61

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.60

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.59

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.58

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.57

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.56

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.55

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.54

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12
• Supplement

Vol.53

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12

Vol.52

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12

Vol.51

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12

Vol.50

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12

Vol.49

• No.1
• No.2/3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12

Vol.48

• No.1
• No.2
• No.3
• No.4
• No.5
• No.6
• No.7
• No.8
• No.9
• No.10
• No.11
• No.12

• Vol.47 to 1
  (Members Only)

• HOME
• Vol.49 No.2/3
• CLINICA NEUROL, 49: 90−95, 2009
• Vol.49 No.2/3 contents

Original Article

Is an oral disintegrating tablets a formulation that is easy to ingest for patients experiencing difficulty with eating and swallowing?

Yoshifumi Umaki, M.D.¹⁾, Sonoko Nozaki, M.D.⁴⁾, Shuhei Sugishita, S.L.P.⁵⁾, Kumiko Shiimoto, S.L.P.²⁾, Shuji Hashiguchi, M.D.¹⁾, Toshio Inui, M.D.¹⁾ and Katsuhito Adachi, M.D.³⁾

¹⁾Department of Neurology, National Hospital Organization Tokushima Hospital
²⁾Department of Rehabilitation, National Hospital Organization Tokushima Hospital
³⁾Department of Internal Medicine, National Hospital Organization Tokushima Hospital
⁴⁾School of Rehabilitation, Department of Physical Therapy, Hyogo University of Health Sciences
⁵⁾Department of Rehabilitation, Takasago Municipal Hospital

Oral disintegrating tablets (hereafter, ODT) can be ingested without water. We conducted a videoscopic examination to determine whether they are also useful as internal agents for patients experiencing difficulty with eating and swallowing. Normal tablets and dummy preparations of ODT were orally administered to six patients with neurological diseases who were either diagnosed with or aware of difficulty in eating and swallowing, and observations were conducted using a videoscope. Two subjects were able to ingest both the normal tablet and the dummy preparation without any problem; two subjects were able to ingest the normal tablet without any problem but the dummy preparation remained in their pharynx; and two subjects had both the normal tablet and the dummy preparation remained in the pharynx. There was no feeling of residue in the four cases in which the dummy preparation remained in the pharynx. ODT is not necessarily easy to ingest for patients with neurological diseases who have difficulty eating and swallowing, and it was believed that repeated swallowing or alternate swallowing of a thick liquid is required for ingestion.
Full Text of this Article in Japanese PDF (604K)

(CLINICA NEUROL, 49: 90−95, 2009)
key words: oral disintegrating tablet, videoendoscopy, dysphagia, drug administration, simple suspension method

(Received: 14-Jul-08)